

# BMJ Open

## Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness (STIFFSLEEP): an observational cohort study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011385
Article Type:	Protocol
Date Submitted by the Author:	03-Feb-2016
Complete List of Authors:	Mineiro, Maria Alexandra; Centro Hospitalar de Lisboa Central, Pneumology Marques da Silva, Pedro; Centro Hospitalar de Lisboa Central, Internal Medicine 4, Arterial Investigation Unit Alves, Marta; Centro Hospitalar de Lisboa Central, Research Unit Virella, Daniel; Centro Hospitalar de Lisboa Central, Research Unit Gomes, M. João Marques ; NOVA Medical School Cardoso, J.; Centro Hospitalar de Lisboa Central, Pneumology; NOVA Medical School
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	SLEEP MEDICINE, Obstructive sleep apnea, Arterial stiffness, Pulse wave velocity

SCHOLARONE™  
Manuscripts

only

**Title:** Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness (STIFFSLEEP): an observational cohort study protocol.

Maria Alexandra Mineiro (1,4), Pedro Marques-da-Silva (2), Marta Alves (3), Daniel Virella (3), Maria João Marques-Gomes (4), João Cardoso (1,4)

1 - Serviço de Pneumologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

2 - Núcleo de Hipertensão Arterial, Consulta de Medicina do Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

3 – Epidemiology and Statistics Unit, Research Centre, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

4 – NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.

Corresponding author: Maria Alexandra Mineiro

Postal address: Rua da Fonte, nº 15-1ºB 1600-457 Lisbon Portugal

e-mail: [xmineiro@gmail.com](mailto:xmineiro@gmail.com)

Telephone: +351 966 382 600

**Keywords:** obstructive sleep apnea, sleepiness, arterial stiffness, pulse wave velocity

**Word count:** 1556

**ABSTRACT**

**Introduction.** Obstructive sleep apnea (OSA) is associated with increased cardiovascular morbidity and mortality. Arterial stiffness, evaluated by pulse wave velocity (PWV), is related to atherosclerosis and cardiovascular (CV) risk. It has been reported that arterial stiffness is higher in patients with OSA than in healthy control groups, with improvement after treatment with Continuous Positive Airway Pressure (CPAP). It is still not known whether the same effect occurs in patients with OSA without daytime hypersomnolence.

**Methods and analysis.** This study aims to evaluate the effect of CPAP therapy in a cohort of patients with moderate to severe OSA; the effect on the subcohorts of sleepy and of non-sleepy patients will be compared. A systematic, consecutive, non-randomized sample of patients proposed to CPAP will be recruited from a single outpatient sleep clinic (Centro Hospitalar de Lisboa Central - CHLC, Portugal). Eligible patients are male, younger than 65 years and with confirmed moderate to severe (AHI>15/h) OSA. Other sleep disorders, diabetes or any CV disease beyond hypertension are exclusion criteria. At baseline, patients proposed to CPAP will have a clinical evaluation, a polygraphic study (cardiorespiratory, level 3), analytical blood evaluation count and the Epworth Sleepiness Scale (ESS) will be applied, score above 10 defines sleepiness. Participants will be proposed to undertake assessment of carotid-femoral pulse wave velocity (CF-PWV) and 24 hours evaluation of Ambulatory Blood Pressure Monitoring (ABPM), before and after 4 months of CPAP therapy. The compliance to CPAP and the effectiveness of CPAP will be assessed. We considered a main outcome changes on CF-PWV over time.

**Ethics and dissemination.** This protocol was approved by the Ethics Committees of both CHLC (ref. 84/2012) and NOVA Medical School (nr.36/2014/CEFCM), Lisbon. Informed, written consent will be obtained. Results will be presented at conferences and published in peer-reviewed journals.

**Registration.** ClinicalTrials.gov ID: NCT02273089.

**BACKGROUND:**

Obstructive sleep apnea (OSA), if left untreated, is associated with high cardio-vascular (CV) morbidity and mortality<sup>1,2,3</sup>.

The diagnosis of OSA syndrome is based on the presence of symptoms suggestive of the disorder, with confirmation by polygraphic sleep study<sup>4,5</sup>. The Epworth Sleepiness Scale (ESS) is frequently used to evaluate the presence of excessive daytime somnolence<sup>6</sup>. Other symptoms besides sleepiness are nonspecific (decreased concentration, irritability)<sup>4,5</sup>, hampering the diagnosis.

Continuous positive airway pressure (CPAP) is the standard therapy for patients with symptomatic OSA, but CPAP therapy for asymptomatic patients is consensual only when the apnea-hypopnea index (AHI) is above 30/hour<sup>7</sup>.

In some studies, a greater severity in polysomnographic parameters has been reported in sleepy patients than in those who are not sleepy<sup>8,9</sup>.

Considering the relationship between OSA and CV disease, namely arterial hypertension or CV risk, it is also less evident in patients with less symptoms. The effect of CPAP in lowering blood pressure (BP) levels seems greater in those patients with more severe OSA and sleepiness than in patients without it<sup>10</sup>.

Changes in arterial distensibility (stiffness) are measurable and are one of the earliest manifestations of functional and structural damage to the vessel wall in the process of atherosclerosis. Arterial stiffness, evaluated by pulse wave velocity (PWV), is used as an early marker of organ damage in hypertensive patients<sup>11</sup>. It predicts cardiovascular events, beyond classical CV risk factors, and can be considered as an intermediate endpoint for CV events<sup>11</sup>. Carotid-femoral pulse wave velocity (CF-PWV), i.e. the speed of the pulse as it travels from the heart to the carotid and the femoral artery, is the most commonly used non-invasive method to assess arterial stiffness and is considered as the gold standard<sup>12,13</sup>.

CF-PWV value is augmented in patients with OSA, even in those without high BP<sup>15,16</sup>. It is augmented even in the less symptomatic, severe patients. Improvement after treatment with CPAP occurs<sup>17</sup> but the effect in patients without sleepiness is less known and still debatable<sup>18</sup>.

1  
2  
3 This research protocol aims to assess the progression of arterial stiffness in two  
4 cohorts of patients with OSA, either sleepy or non-sleepy, while undergoing treatment  
5 with CPAP. We hypothesize that a measurable improvement on the control of CF-PWV  
6 can be detected over time independently of sleepiness.  
7  
8  
9

## 10 11 12 **METHODS AND ANALYSIS**

### 13 **Study design**

14  
15  
16 This project involves the prospective, observational study of a systematic, consecutive,  
17 non-randomized sample of adult male patients diagnosed with OSA and proposed to  
18 CPAP, recruited from a single outpatient sleep clinic (Centro Hospitalar de Lisboa  
19 Central - CHLC, Lisbon, Portugal).  
20  
21  
22

23  
24 Eligible patients are male, younger than 65 years and with confirmed moderate to  
25 severe (AHI>15/h) OSA. The sample is divided into two cohorts according to the  
26 Epworth sleepiness scale (ESS) and the effect of CPAP therapy on sleepy and of non-  
27 sleepy patients will be compared.  
28  
29

30  
31 The primary outcome measure is the variation of CF-PWV after therapy with CPAP.  
32  
33

34  
35 The secondary outcomes are:

- 36 - the decline of the severity of OSA assessed by the AHI and oxygen saturation,
  - 37 - ambulatory blood pressure measurements (ABPM) variations
  - 38 - the lipidic profile and metabolic changes after treatment with CPAP.
- 39  
40  
41  
42

43  
44 Each patient will be its own control, for ethical reasons. The effect of a three months  
45 trial of CPAP will be assessed.  
46  
47

48  
49 The study is exploratory in nature and is based on a convenience sample, limited by  
50 the number of eligible patients consenting to participate. Recruitment started on  
51 October 2012 and data collection is expected to end by June 2016.  
52  
53  
54

### 55 **Inclusion criteria**

56  
57  
58  
59  
60

Patients referred to the Outpatient Sleep Clinic of the Pneumology Department, CHLC, Lisbon, due to snoring or other complaints suggestive of OSA, are eligible for the study if they are male, younger than 65 years old and OSA of moderate to severe degree (AHI > 15 / h) is confirmed.

#### Exclusion criteria:

Patients are excluded if they have any established heart disease beyond arterial hypertension, peripheral vascular disease or a history of cardiovascular events; if they have other chronic diseases, excessive alcohol intake (> 80 g / day), chronic ingestion of hypnotics or other clinically identified sleep disorders. Some comorbidities are allowed, namely metabolic syndrome. Antihypertensive medication and treatment of dyslipidaemia are admitted.




Fig.1 Design of the study.

### Baseline evaluation

The protocol of the Outpatient Sleep Clinic requires that patients referred due to snoring or other complaints suggestive of OSA will be the proposed a clinical evaluation, in which the suspected OSA is confirmed. The severity of sleepiness is assessed using ESS. The presence of comorbidities and pharmacotherapy in progress is evaluated. Anthropometric data regarding adiposity and vital signs are collected.

For the diagnosis of OSA, every patient is submitted to a polygraphic sleep study type 3, cardiorespiratory (Embletta® system, Broomfield, USA), a technical outpatient registration, which includes the continuous recording from nasal cannulae (pressure and flow), thoracic-abdominal motion, pulse oxymetry, electrocardiogram and body position sensor. Results from the sleep studies are analyzed by two trained technicians, using standard criteria<sup>19</sup>.

ESS is applied by the principal investigator, as part of the first clinical evaluation after referral.

An analytical screening evaluation will be done, including HbA1c, fasting glucose, total cholesterol, HDL-col, LDL-col and triglycerides.

Patients will be further proposed to undertake the following diagnostic techniques:

- body composition assessment, estimating the proportion of fat mass ref by tetrapolar bioimpedance, operated by the same technician (OMRON HBF- 510, Texas, USA);
- ECG (Page Writer TC 30, Philips), operated by the same technicians, as per institutional protocol;
- Ambulatory Blood Pressure Monitoring (ABPM), with Ambulatory Blood Pressure - SpaceLabs model 90207®, according current guidelines.
- noninvasive automatic assessment of CF-PWV (Complior®, Colson, Paris, France), performed by the same operator.

The assessment of pulse wave velocity is performed with the patient in the supine position, and the values take in account the blood pressure value, which in turn is measured first, at least twice at the upper arm and the average values obtained. CF-PWV is usually measured using the «foot-to-foot» velocity method from the pressure

1  
2  
3 waveforms, obtained using surface tonometry probes at the right common carotid  
4 artery and the right femoral artery. The time delay (Dt, or transit time) is measured  
5 between the «foot» of these two waveforms. The distance D covered by the waves is  
6 incorporated to the skin distance the two tonometry probes, i.e. the common carotid  
7 artery and the common femoral artery. PWV is estimated as  $PWV=D/Dt$  (m/s)<sup>12</sup>.

8  
9 Measurements will always be performed in the morning, without prior intake of tea or  
10 coffee.

11  
12 Participants will be classified by the results of the ESS as Sleepy (ESS > 10) and Non-  
13 sleepy (ESS ≤ 10).

14  
15 Patients will be classified as normotensive if the average systolic and diastolic blood  
16 pressure values obtained by ABPM are within normal limits. Patients will be classified  
17 as hypertensive if already on antihypertensive medication or if the average blood  
18 pressure values obtained by ABPM are above ≥130 mmHg of systolic and/or ≥80  
19 mmHg diastolic blood pressure<sup>11</sup>.

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Dyslipidaemia, glucose intolerance and metabolic syndrome will be diagnosed  
according to the criteria of current guidelines<sup>20</sup>.

### Standard CPAP Intervention

According to current clinical recommendations,<sup>4</sup> patients with moderate or severe  
OSA, are proposed therapy with noninvasive ventilation by CPAP. Additionally, patients  
receive sleep hygiene advice.

CPAP titration is performed using an automatic auto-CPAP device (ResMed S9 AutoSet,  
California, USA) for 3 nights. The definitive value of CPAP is the amount of pressure  
that eliminates events in about 95% of the total sleep time (95<sup>th</sup> percentile), once  
confirmed there is not significant leakage and nasal mask is used<sup>21</sup>.

Patients will be evaluated at the end of the first, second and third months, for  
assessment of the compliance with and the effectiveness of the intervention. The  
compliance to the CPAP is measured by the automatic reading of the CPAP's card; a  
patient is considered as compliant when using CPAP at least 4h/day as the average of



1  
2  
3 at least 70% of nights. CPAP is considered as effective if the AHI falls below 10/h and  
4 the reduction is at least 50% of the baseline AHI<sup>22</sup>.  
5  
6

7 The presence of nasal complaints or changes on the equipment will be considered.  
8  
9

### 10 11 **Follow up assessments** 12

13 After 4 months of standard CPAP intervention, the following evaluation will be  
14 proposed:  
15

- 16 - Clinical evaluation (ESS),
  - 17 - assessment of compliance to CPAP and evaluation of the effectiveness of therapy,
  - 18 - body composition assessment,
  - 19 - ABPM, CF-PWV and analytical evaluation (similar to baseline).
- 20  
21  
22  
23  
24

25 At this point, patients are excluded from follow up if significant weight loss (greater  
26 than 5%) occurs<sup>4</sup>, if new drugs had been prescribed or new diseases are diagnosed.  
27  
28  
29

### 30 31 **Statistical analyses** 32

33 Continuous variables are described with median and interquartile range (IQR, 25th  
34 percentile to 75th percentile) or extreme values, and were compared using the Mann-  
35 Whitney test. Categorical variables are described as percentage and were compared  
36 with Pearson's chi-square test or Fisher's exact test, and stratified Mantel-Haenszel  
37 analysis was performed as appropriate.  
38  
39

40 The primary outcome measure (CF-PWV) will be compared before and after therapy  
41 with CPAP for three months. Analysis will be performed as per intention to treat,  
42 considering the outcome measures both as continuous and categorical variables.  
43 Continuous variables will be compared as paired samples, using parametric or non-  
44 parametric tests as adequate. Categorized outcome measures will be used to estimate  
45 incidence rates of the outcomes and relative risk estimates, both with 95% confidence  
46 intervals, using [www.openepi.com](http://www.openepi.com).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Univariable logistic regression analysis will be performed to explore associations  
4 between outcomes and exposures, in order to assess factors influencing the success of  
5 the intervention.  
6  
7  
8  
9

10  
11 **Contributors** All authors provided intellectual input into the editing of the manuscript  
12 and preparation of publication.  
13

14  
15 **Funding** The work was supported by Pneumology Department, CHLC, Lisbon, and  
16 Vitalaire SA.  
17

18  
19 **Competing interests** None  
20

21 **Patient consent** Obtained  
22

23  
24 **Provenance and peer review** Not commissioned; externally peer reviewed  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Young T, Finn L, Peppard PE, Szklo-Coxe M, Austin D, Nieto FJ et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin Sleep Cohort. *Sleep* 2008; 31: 1071-78.
2. Marin JM, Carrizo SJ, Vicente E, Agusti AGN, Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005; 365: 1046-53.
3. Peker Y, Hedner J, Norum J, Kraiczi H, Carlson J. Increased Incidence of Cardiovascular Disease in Middle-aged Men with Obstructive Sleep Apnea. A 7-Year Follow-up. *Am J Respir Crit Care Med* 2002; 166: 159–65.
4. Epstein LJ, Kristo D, Strollo PJ, Friedman N, Malhotra A, Patil SP et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep medicine. *Journal of Clinical Sleep Medicine* 2009; 5 (nº3): 263-76.
5. McNicholas WT. Diagnosis of Obstructive Sleep Apnea in Adults. *Proc Am Thorac Soc* 2008; 5: 154–60.
6. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991; 14:540-5.
7. Lloberes P., Durán-Cantolla J., Martínez-García MA., Marín JM., Ferrer A., Corral J., Masa KF., Parra O., Alonso-Álvarez ML., Terán-Santos J.. SEPAR Guidelines Diagnosis and treatment of sleep apnea-hypopnea syndrome. *ArchBronconeumol*. 2011;47(3):143-156
8. Oksenberg A. et al. Severe obstructive sleep apnea: sleepy versus non sleepy patients. *Laryngoscope* 2010 Mar; 120 (3): 643-8.
9. Kapur VK, Baldwin CM, Resnick HE, Gottlieb DJ, Nieto J. Sleepiness in patients with moderate to severe sleep-disordered breathing. *Sleep* 2005; 28(4); 472-77
10. Bratton DJ, Stradling JR, Barbé F, Kohler M. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis

1  
2  
3 using individual patient data from four randomised controlled trials. *Thorax*  
4 2014;0:1–8.  
5

- 6  
7 11. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013  
8 Guidelines for the Management of Arterial Hypertension: The Task Force for  
9 the Management of Arterial Hypertension of the European Society of  
10 Hypertension (ESH) and of the European Society of Cardiology (ESC). *Journal of*  
11 *Hypertension* 2013; 31:1281–1357.  
12  
13 12. Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cifková R, Cosentino F,  
14 et al. The role of vascular biomarkers for primary and secondary prevention. A  
15 position paper from the European Society of Cardiology Working Group on  
16 peripheral circulation: Endorsed by the Association for Research into Arterial  
17 Structure and Physiology (ARTERY) Society. *Atherosclerosis* 2015; 241(2): 507-  
18 532.  
19  
20 13. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events  
21 and all-cause mortality with arterial stiffness. A systematic review and meta-  
22 analysis. *JACC* 2010; 55 (nº13): 1318-27.  
23  
24 14. Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De  
25 Backer T, et al. Expert consensus document on the measurement of aortic  
26 stiffness in daily practice using carotid-femoral pulse wave velocity. *J.*  
27 *Hypertens.* 2012; 30: 445-448.  
28  
29 15. Doonan RJ, Scheffler P, Lalli M, Kimoff RJ, Petridou ET, Daskalopoulos ME, et al..  
30 Increased arterial stiffness in obstructive sleep apnea: a systematic review.  
31 *Hypertension Research* 2011; 34: 23-32.  
32  
33 16. Drager LF, Bortolotto LA, Lorenzi MC, Figueiredo AC, Krieger EM, Lorenzi-Filho  
34 G. Early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit*  
35 *Care Med* 2005; 172:613-18.  
36  
37 17. Vlachantoni IT, Dikaiakou E, Antonopoulos C, Stefanadis C, Daskalopoulou S,  
38 Petridou ET. Effects of continuous positive airway pressure (CPAP) treatment  
39 for obstructive sleep apnea in arterial stiffness: A meta-analysis. *Sleepmedicine*  
40 *reviews* 2013; 17 (1): 19-28.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 18. Wons AM, Kohler M. Established vascular effects of continuous positive airway  
4 pressure therapy in patients with obstructive sleep apnoea – an update. J  
5 Thorac Dis 2015; 7(5):912-919.  
6  
7  
8  
9 19. Iber CI, Ancoli-Israel S, Chesson L, Quan S: for the American Academy of Sleep  
10 Medicine. Rules, terminology and technical specifications: The AASM Manual  
11 for Scoring of Sleep and Associated Events; 2007.  
12  
13 20. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel H, Franklin BA, et al.  
14 Diagnosis and management of the metabolic syndrome. An American Heart  
15 Association/National Heart, Lung, and Blood Institute Scientific Statement.  
16 Circulation 2005; 112:2735-52.  
17  
18 21. Masa JF, Jiménez A., Duran J., Capote F., Monasterio C., Mayos M, et al.  
19 Alternative Methods of Titrating Continuous Positive Airway Pressure. A Large  
20 Multicenter Study. Am J Respir Crit Care Med 2004; 170: 1218-1224  
21  
22 22. Schwab RJ, Badr SM, Epstein LJ, Gay PC, Gozal D, Kohler M. An Official American  
23 Thoracic Society Statement: Continuous Positive Airway Pressure Adherence  
24 Tracking Systems. The optimal monitoring strategies and outcome measures in  
25 adults. Am J Respir Crit Care Med 2013; 188 (5): 613-620.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness(STIFFSLEEP): an observational cohort study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011385.R1
Article Type:	Protocol
Date Submitted by the Author:	24-Mar-2016
Complete List of Authors:	Mineiro, Maria Alexandra; Centro Hospitalar de Lisboa Central, Pneumology Marques da Silva, Pedro; Centro Hospitalar de Lisboa Central, Internal Medicine 4, Arterial Investigation Unit Alves, Marta; Centro Hospitalar de Lisboa Central, Epidemiology and Statistics Unit, Research Centre Virella, Daniel; Centro Hospitalar de Lisboa Central, Epidemiology and Statistics Unit, Research Center Gomes, M. João Marques ; NOVA Medical School Cardoso, J.; Centro Hospitalar de Lisboa Central, Pneumology; NOVA Medical School
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Obstructive sleep apnea, Sleepiness, Pulse wave velocity, Arterial stiffness

SCHOLARONE™  
Manuscripts

**Title:** Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnoea, Without Excessive Daytime Sleepiness (STIFFSLEEP): an observational cohort study protocol.

Maria Alexandra Mineiro (1,4), Pedro Marques-da-Silva (2), Marta Alves (3), Daniel Virella (3), Maria João Marques-Gomes (4), João Cardoso (1,4)

1 - Serviço de Pneumologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

2 - Núcleo de Investigação Arterial, Medicina IV, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

3 – Epidemiology and Statistics Unit, Research Centre, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

4 – NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.

Corresponding author: Maria Alexandra Mineiro

Postal address: Rua da Fonte, nº 15-1ºB 1600-457 Lisbon Portugal

E-mail: [xmineiro@gmail.com](mailto:xmineiro@gmail.com)

Telephone: +351 966 382 600

**Keywords:** obstructive sleep apnoea, sleepiness, arterial stiffness, pulse wave velocity

**ABSTRACT**

**Introduction.** Sleepiness is a cardinal symptom in obstructive sleep apnoea (OSA), but most patients have unspecific symptoms. Arterial stiffness, evaluated by pulse wave velocity (PWV), is related to atherosclerosis and cardiovascular (CV) risk. It has been reported that arterial stiffness is higher in patients with OSA, with improvement after treatment with Continuous Positive Airway Pressure (CPAP). It is still not known whether the same effect occurs in patients with OSA without sleepiness.

**Methods and analysis.** This study aims to evaluate the effect of CPAP therapy in a cohort of patients with moderate to severe OSA; the effect on the subcohorts of sleepy and of non-sleepy patients will be compared. A systematic, consecutive, non-randomized sample of patients proposed to CPAP will be recruited from a single outpatient sleep clinic (Centro Hospitalar de Lisboa Central - CHLC, Portugal). Eligible patients are male, younger than 65 years and with confirmed moderate to severe OSA, Apnea-Hypopnea Index (AHI) above 15/h. Other sleep disorders, diabetes or any CV disease beyond hypertension are exclusion criteria. At baseline, patients will have a clinical evaluation, including Epworth Sleepiness Scale (ESS). Sleepiness is defined as ESS above 10. OSA will be confirmed by polygraphic study (cardiorespiratory, level 3). Patients will be proposed to undertake assessment of carotid-femoral pulse wave velocity (cfPWV) and 24 hours evaluation of Ambulatory Blood Pressure Monitoring (ABPM), before and after 4 months of CPAP therapy. The compliance to CPAP and the effectiveness of CPAP will be assessed. We considered a main outcome changes on cfPWV over time.

**Ethics and dissemination.** This protocol was approved by the Ethics Committees of both - CHLC (ref. 84/2012) and NOVA Medical School (nr.36/2014/CEFCM), Lisbon. Informed, written consent will be obtained. Results will be presented at conferences and published in peer-reviewed journals.

**Registration.** ClinicalTrials.gov ID: NCT02273089.



### Strengths and limitations of this study protocol

- This study protocol allows obtaining new evidence about the effectiveness of CPAP to decrease cardio-vascular risk in sleepy and non-sleepy male patients with OSA.
- The strengths of this protocol are the controlled, clinic-based setting, the use of standardized instruments to characterize OSA and sleepiness, and the use of standardized quantitative early indicators of cardio-vascular risk (cf-PWV).
- This observational study protocol has the limitations of the convenience, non-randomized sample and the exclusion of patients with mild OSA or elder patients.

### BACKGROUND:

Obstructive sleep apnoea (OSA), if left untreated, is associated with high cardio-vascular (CV) morbidity and mortality<sup>1,2,3</sup>.

The diagnosis of OSA syndrome is based on the presence of symptoms suggestive of the disorder, with confirmation by polygraphic sleep study<sup>4,5</sup>. The Epworth Sleepiness Scale (ESS) is a validated questionnaire to evaluate the presence of excessive daytime somnolence<sup>6</sup>. Other symptoms besides sleepiness are nonspecific (decreased concentration, irritability)<sup>4,5</sup>, hampering the diagnosis.

Continuous positive airway pressure (CPAP) is the standard therapy for patients with symptomatic OSA, but CPAP therapy for asymptomatic patients is consensual only when the apnea-hypopnea index (AHI) is above 30/hour<sup>7</sup>.

In some studies, a greater severity in polysomnographic parameters has been reported in sleepy patients than in those who are not sleepy<sup>8,9</sup>.

Considering the relationship between OSA and CV disease, namely arterial hypertension or CV risk, it is also less evident in patients with less symptoms. The effect of CPAP in lowering blood pressure (BP) levels seems greater in those patients with more severe OSA and sleepiness than in patients without it<sup>10</sup>.

Changes in arterial stiffness are measurable and are one of the earliest manifestations of functional and structural damage to the vessel wall in the process of atherosclerosis. Arterial stiffness, evaluated by pulse wave velocity (PWV), is used as an early marker of

1  
2  
3 organ damage in hypertensive patients<sup>11</sup>. It predicts cardiovascular events, beyond  
4 classical CV risk factors, and can be considered as an intermediate endpoint for CV  
5 events<sup>12</sup>. Carotid-femoral pulse wave velocity (cf-PWV), i.e. the speed of the pulse as it  
6 travels from the heart to the carotid and the femoral artery, is the most commonly  
7 used non-invasive method to assess arterial stiffness and is considered as the gold  
8 standard<sup>12,13</sup>.

9  
10 Increased arterial stiffness depends on various conditions, of which blood pressure and  
11 ageing are dominant, but also other CV risk factors.

12  
13  
14 cf-PWV value is augmented in patients with OSA, even in those without high BP<sup>15,16</sup>. It  
15 is augmented even in the less symptomatic, severe patients. Improvement after  
16 treatment with CPAP occurs<sup>17</sup> but the effect in patients without sleepiness is less  
17 known and still debatable<sup>18</sup>.

18  
19  
20 This research protocol aims to assess the progression of arterial stiffness in two  
21 cohorts of patients with OSA, either sleepy or non-sleepy, while undergoing treatment  
22 with CPAP. We hypothesize that a measurable improvement on the control of cf-PWV  
23 can be detected over time independently of sleepiness.

24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

## METHODS AND ANALYSIS

### Study design

This project involves the prospective, observational study of a systematic, consecutive, non-randomized sample of adult male patients diagnosed with OSA and proposed to CPAP, recruited from a single outpatient sleep clinic (Centro Hospitalar de Lisboa Central - CHLC, Lisbon, Portugal).

Eligible patients are male, younger than 65 years and with confirmed moderate to severe OSA (AHI>15/h), who are residents in Greater Lisbon. The sample is divided into two cohorts according to the Epworth sleepiness scale (ESS) and the effect of CPAP

1  
2  
3 therapy on sleepy (ESS>10) and of non-sleepy (ESS≤10) patients will be compared  
4 (Fig.1).  
5

6  
7 We considered as a primary outcome measure the variation of cf-PWV after therapy  
8 with CPAP.  
9

10  
11 The secondary outcomes are:

- 12 - the decline of the severity of OSA assessed by the AHI
  - 13 - ambulatory blood pressure measurements (ABPM) variations
  - 14 - the lipid profile and metabolic changes after treatment with CPAP.
- 15  
16  
17  
18  
19

20 Each patient will be its own control, for ethical reasons. The effect of a four months  
21 trial of CPAP will be assessed.  
22

23  
24 The study is exploratory in nature and is based on a convenience sample, limited by  
25 the number of eligible patients consenting to participate. Sample size was estimated  
26 for the primary outcome measure as an effective sample of 70 patients to  
27 demonstrate a reduction on cfPWV from 12 m/s to 11 m/s (before and after 4 months  
28 on CPAP), with 95% confidence and power 80%. Based on the previous assessment of  
29 the institutional experience on compliance with CPAP and with outpatient clinic  
30 consultations, the recruited sample was increased in 15% to 80 patients.  
31  
32

33  
34 Recruitment started on October 2012 and data collection is expected to end by June  
35 2016.  
36  
37  
38  
39  
40  
41  
42

### 43 **Inclusion criteria**

44  
45 Patients referred to the Outpatient Sleep Clinic of the Pneumology Department, CHLC,  
46 Lisbon, due to snoring or other complaints suggestive of OSA, are eligible for the study  
47 if they are male, younger than 65 years old, residents in Greater Lisbon and OSA of  
48 moderate to severe degree (AHI> 15 / h) is confirmed. The Epworth questionnaire is to  
49 be completed during the first consultation, and data on anamnesis and clinical  
50 examination will be collected.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Exclusion criteria:**

Patients are excluded if they have a history of cardiovascular events; established heart disease (beyond arterial hypertension); peripheral vascular disease. Smoking (over 10 units pack year) or alcohol intake (> 80 g / day) are not allowed. Other severe chronic illnesses (assessed by chronic use of medication), chronic ingestion of hypnotics or other sleep disorders (identified clinically) are exclusion criteria.

Patients with diabetes were excluded, as they might have vascular involvement. In patients with glucose intolerance, oral glucose tolerance test will be performed.

Some comorbidities, are allowed, namely hypertension and metabolic syndrome. Antihypertensive medication and treatment of dyslipidemia are allowed.

**Baseline evaluation**

The protocol of the Outpatient Sleep Clinic requires that patients referred due to snoring or other complaints suggestive of OSA will be the proposed a clinical evaluation, in which the suspected OSA is confirmed. The presence of comorbidities and pharmacotherapy in progress is evaluated. The duration of either comorbidity or pharmacotherapy was not considered to be collected as including them as accountable intervening factors would greatly increase the sample size. Anthropometric data regarding adiposity and vital signs are collected.

For the diagnosis of OSA, every patient is submitted to a polygraphic sleep study type 3, cardiorespiratory (Embletta® system, Broomfield, USA), a technical outpatient registration, which includes the continuous recording from nasal cannula (pressure and flow), thoracic-abdominal motion, pulse oximetry, electrocardiogram and body position sensor. Results from the sleep studies are analyzed by two trained technicians, using standard criteria<sup>20</sup>.

ESS is applied by the principal investigator, as part of the first clinical evaluation after referral.

1  
2  
3 An analytical screening evaluation will be done, including HbA1c, fasting glucose, total  
4 cholesterol, HDL, LDL and triglycerides; and an ECG (Page Writer TC 30, Philips,  
5 Eindhoven, NL), operated by the same technicians, as per institutional protocol.  
6  
7

8 Patients will be further proposed to undertake the following diagnostic techniques:  
9

- 10  
11 - Ambulatory Blood Pressure Monitoring (ABPM), with Ambulatory Blood Pressure -  
12 SpaceLabs model 90207® (Issaquah, WZ, USA), according current guidelines.  
13

14  
15 Patients will be classified as normotensive if the average systolic and diastolic BP  
16 values obtained by ABPM are within normal limits; and will be classified as  
17 hypertensive if already on antihypertensive medication or if the average BP values  
18 obtained by ABPM are above  $\geq 130$  mmHg of systolic and/or  $\geq 80$  mmHg diastolic blood  
19 pressure<sup>11</sup>. Patients with successfully pharmacologically controlled hypertension are  
20 considered normotensive for this matter.  
21  
22  
23  
24

- 25  
26  
27  
28 - noninvasive assessment of cf-PWV (Complior®, Colson, Paris, France), performed  
29 by the same operator.  
30  
31

32 At first, weight and height will be assessed. Body mass index (BMI) is calculated using  
33 the following formula – weight (kg) divided by height (m<sup>2</sup>).  
34

35  
36 Office BP is measured using a semi-automatic device (Omron HEM-907XL, Omron  
37 Healthcare, Bannockburn, IL, USA) with the use of an appropriate cuff in a quiet room  
38 in a seated position. The patient did not smoke or take any stimulant substance during  
39 the 3 h prior to the BP assessment. Two measurements are taken with a minimum of 3-  
40 min intervals and the average was considered. When large differences existed among  
41 them, additional measurements were performed. Pulse pressure is calculated as SBP  
42 minus DBP.  
43  
44  
45  
46  
47

48 For the evaluation of cf-PWV is used the Complior device. User procedures and patient  
49 management were followed according to the recently published expert consensus  
50 document<sup>14</sup>. Briefly, measurement is done at the right common carotid and right  
51 common femoral arteries after 10 min of rest in supine position. Two pressure  
52 waveforms were transcutaneously recorded at the base of the neck for the right  
53 common carotid artery and over the right femoral artery. Pulse transit time was  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 determined as the average of 10 consecutive beats. The straight-line distance between  
4 the measurement sites is obtained by surface measurement, with the patient in the  
5 supine position. cf-PWV is calculated as the ratio of distance to transit time. The  
6 threshold for cf-PWV evaluated by the full direct carotid-to-femoral distance has been  
7 revised in a recent consensus to 10 m/s<sup>14</sup>, in order to normalize cf-PWV values  
8 according to the arterial pathway.

9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
Dyslipidemia, glucose intolerance and metabolic syndrome will be diagnosed according  
to the criteria of current guidelines<sup>21</sup>.

### Standard CPAP Intervention

According to current clinical recommendations,<sup>4</sup> patients with moderate or severe  
OSA, are proposed therapy with noninvasive ventilation by CPAP. Additionally, patients  
receive sleep hygiene advice.

CPAP titration will performed using an automatic auto-CPAP device (ResMed S9  
AutoSet, California, USA) for 3 nights. The definitive value of CPAP is the amount of  
pressure that eliminates events in about 95% of the total sleep time (95<sup>th</sup> percentile),  
once confirmed there is not significant leakage and nasal mask is used<sup>22</sup>.

Patients will be evaluated monthly, for assessment of compliance and effectiveness of  
the intervention. The compliance to the CPAP will be measured by downloading CPAP's  
card; a patient is considered as compliant when using CPAP at least 4h/day as the  
average of at least 70% of nights. CPAP is considered as effective if the AHI falls below  
5/h<sup>23</sup>.

The presence of nasal complaints or changes on the equipment will be considered.

### Follow up assessments

After 4 months of standard CPAP intervention, the following evaluation will be  
proposed:

- Clinical evaluation (ESS)
- assessment of compliance to CPAP and evaluation of the effectiveness of therapy

- BMI, ABPM, cf-PWV and analytical evaluation (similar to baseline)

At this point, patients are excluded from follow up if they were not compliant to CPAP. Also, if significant weight loss (greater than 10%) occurs<sup>4</sup>, if new drugs had been prescribed or new diseases are diagnosed.

### Statistical analyses

Continuous variables are described with median and interquartile range (IQR, 25th percentile to 75th percentile) or extreme values, as previous evaluations have evidenced that a normal distribution of values was not to be expected. The comparisons between sleepy and non-sleepy subjects at each evaluation moment are made using the Mann-Whitney test. Categorical variables are described as percentage and were compared with Pearson's chi-square test or Fisher's exact test, and stratified Mantel-Haenszel analysis was performed as appropriate. Measurements on the cohort subjects before and after 4 months of CPAP will be analyzed using generalized linear mixed-effects models for repeated longitudinal data, to explore associations between outcomes and exposures, in order to assess factors influencing the success of the intervention.

The primary outcome measure (cf-PWV) will be compared before and after therapy with CPAP for four months. Analysis will be performed as per intention-to-treat.

Categorized outcome measures will be used to estimate incidence rates of the outcomes and relative risk estimates, both with 95% confidence intervals.

### Discussion:

The results of this study will disclose differences in the CV risk and the response to CPAP therapy between patients with and without daytime sleepiness. In the subgroup of less symptomatic patients, the benefits of CPAP have to be identified.

This observational study protocol has the limitations of the convenience, non-randomized sample, and the exclusion of patients with mild OSA or elder patients. The strengths of this protocol are the controlled, clinic-based setting, the use of

1  
2  
3 standardized instruments to characterize OSA and sleepiness, and the use of  
4 standardized quantitative early indicators of cardio-vascular risk (cfPWV), a useful  
5 indicator of subclinical CV disease.  
6  
7  
8  
9

### 10 11 **Ethics and dissemination**

12 This protocol was approved by the Ethics Committees of both CHLC (ref. 84/2012) and  
13 NOVA Medical School (nr.36/2014/CEFCM), Lisbon. It has been registered as  
14 STIFFSLEEP at ClinicalTrials.gov (ID: NCT02273089). Informed, written consent will be  
15 obtained. Results will be presented at conferences and published in peer-reviewed  
16 journals.  
17  
18  
19  
20  
21  
22  
23

24  
25 **Funding statement:** This work was supported by the Pneumology Department, CHLC,  
26 Lisbon, and by a gracious grant from Vitalaire SA (Lisbon).  
27  
28

### 29 **Acknowledgements**

30  
31 **Author's contributors:** Alexandra Mineiro developed the conceptual clinical  
32 background of the protocol; Pedro Marques-da-Silva provided clinical background and  
33 methodological input for the cardiovascular risk assessment; Marta Alves and Daniel  
34 Virella contributed to the epidemiologic design, causal framework and proposed  
35 epidemiologic and statistical analyses; Maria João Marques-Gomes and João Cardoso  
36 provided scientific overview. All authors provided intellectual input into the editing of  
37 the manuscript and preparation of publication.  
38  
39  
40  
41  
42  
43  
44  
45

46 **Funding** The work was supported by Pneumology Department, CHLC, Lisbon, and  
47 Vitalaire SA.  
48

49 **Competing interests** None  
50

51 **Patient consent** Obtained  
52

53 **Provenance and peer review** Not commissioned; externally peer reviewed  
54  
55  
56  
57  
58  
59  
60



## REFERENCES

1. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin Sleep Cohort. *Sleep* 2008;31:1071-78.
2. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet* 2005;365:1046-53.
3. Peker Y, Hedner J, Norum J, et al. Increased Incidence of Cardiovascular Disease in Middle-aged Men with Obstructive Sleep Apnea. A 7-Year Follow-up. *Am J Respir Crit Care Med* 2002;166:159–65.
4. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep medicine. *Journal of Clinical Sleep Medicine* 2009;5(nº3):263-76.
5. McNicholas WT. Diagnosis of Obstructive Sleep Apnea in Adults. *Proc Am Thorac Soc* 2008;5:154–60.
6. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14:540-5.
7. Lloberes P, Durán-Cantolla J, Martínez-García MA, et al. SEPAR Guidelines. Diagnosis and treatment of sleep apnea-hypopnea syndrome. *ArchBronconeumol*. 2011;47(3):143-156
8. Oksenberg A. et al. Severe obstructive sleep apnea: sleepy versus non sleepy patients. *Laryngoscope* 2010 Mar; 120 (3): 643-8.
9. Kapur VK, Baldwin CM, Resnick HE, et al. Sleepiness in patients with moderate to severe sleep-disordered breathing. *Sleep* 2005; 28(4); 472-77
10. Bratton DJ, Stradling JR, Barbé F, et al. Effect of CPAP on blood pressure in patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis using individual patient data from four randomised controlled trials. *Thorax* 2014;0:1–8.
11. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial

- Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J. Hypertens.* 2013; 31:1281–1357.
12. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. *Atherosclerosis* 2015;241(2):507-532.
  13. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness. A systematic review and meta-analysis. *JACC* 2010; 55 (nº13):1318-27.
  14. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. *J. Hypertens.* 2012;30:445-448.
  15. Doonan RJ, Scheffler P, Lalli M, et al. Increased arterial stiffness in obstructive sleep apnoea: a systematic review. *Hypertension Research* 2011;34:23-32.
  16. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. *Am J Respir Crit Care Med* 2005;172:613-18.
  17. Vlachantoni IT, Dikaiakou E, Antonopoulos C, et al. Effects of continuous positive airway pressure (CPAP) treatment for obstructive sleep apnea in arterial stiffness: A meta-analysis. *Sleep Med Rev* 2013;17(1):19-28.
  18. Wons AM, Kohler M. Established vascular effects of continuous positive airway pressure therapy in patients with obstructive sleep apnoea – an update. *J Thorac Dis* 2015;7(5):912-919.
  19. Mota PC, Drummond M, Winck JC, et al. APAP impact on metabolic syndrome in obstructive sleep apnea patients. *Sleep Breath* 2011;15(4):665-72.
  20. Iber CI, Ancoli-Israel S, Chesson L, et al. for the American Academy of Sleep Medicine. Rules, terminology and technical specifications: *The AASM Manual for Scoring of Sleep and Associated Events*; 2007.
  21. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International

Atherosclerosis Society; and International Association for the Study of Obesity.

*Circulation* 2009 Oct20;120(16):1640-5

22. Masa JF, Jiménez A., Duran J., et al. Alternative Methods of Titrating Continuous Positive Airway Pressure. A Large Multicenter Study. *Am J Respir Crit Care Med* 2004;170:1218-1224

23. Schwab RJ, Badr SM, Epstein LJ, et al. An Official American Thoracic Society Statement: Continuous Positive Airway Pressure Adherence Tracking Systems. The optimal monitoring strategies and outcome measures in adults. *Am J Respir Crit Care Med* 2013;188(5):613-620.

peer review only




Fig.1 Study design  
173x233mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnoea, Without Excessive Daytime Sleepiness (STIFFSLEEP): an observational cohort study protocol.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2016-011385.R2
Article Type:	Protocol
Date Submitted by the Author:	08-May-2016
Complete List of Authors:	Mineiro, Maria Alexandra; Centro Hospitalar de Lisboa Central, Pneumology; NOVA Medical School Marques da Silva, Pedro; Centro Hospitalar de Lisboa Central, Internal Medicine 4, Arterial Investigation Unit Alves, Marta; Centro Hospitalar de Lisboa Central, Epidemiology and Statistics Unit, Research Centre Virella, Daniel; Centro Hospitalar de Lisboa Central, Epidemiology and Statistics Unit, Research Center Gomes, M. João Marques ; NOVA Medical School Cardoso, J.; Centro Hospitalar de Lisboa Central, Pneumology; NOVA Medical School
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Cardiovascular medicine
Keywords:	Obstructive sleep apnea, Sleepiness, Pulse wave velocity, Arterial stiffness

SCHOLARONE™  
Manuscripts

**Title:** Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnoea, Without Excessive Daytime Sleepiness (STIFFSLEEP): an observational cohort study protocol.

Maria Alexandra Mineiro (1,4), Pedro Marques da Silva (2), Marta Alves (3), Daniel Virella (3), Maria João Marques Gomes (4), João Cardoso (1,4)

1 - Serviço de Pneumologia, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

2 - Núcleo de Investigação Arterial, Medicina IV, Hospital de Santa Marta, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

3 – Epidemiology and Statistics Unit, Research Centre, Centro Hospitalar de Lisboa Central, Lisbon, Portugal.

4 – NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal.

Corresponding author: Maria Alexandra Mineiro

Postal address: Rua da Fonte, nº 15-1ºB 1600-457 Lisbon Portugal

E-mail: [xmineiro@gmail.com](mailto:xmineiro@gmail.com)

Telephone: +351 966 382 600

**Keywords:** obstructive sleep apnoea, sleepiness, arterial stiffness, pulse wave velocity

**Word count:** 2083

**ABSTRACT**

**Introduction.** Sleepiness is a cardinal symptom in obstructive sleep apnoea (OSA) but most patients have unspecific symptoms. Arterial stiffness, evaluated by pulse wave velocity (PWV), is related to atherosclerosis and cardiovascular (CV) risk. Arterial stiffness was reported to be higher in patients with OSA, improving after treatment with Continuous Positive Airway Pressure (CPAP). This study aims to assess whether the same effect occurs in patients with OSA and without sleepiness.

**Methods and analysis.** This observational study assesses the CV effect of CPAP therapy on a cohort of patients with moderate to severe OSA; the effect on the subcohorts of sleepy and of non-sleepy patients will be compared. A systematic, consecutive sample of patients proposed to CPAP will be recruited from a single outpatient sleep clinic (Centro Hospitalar de Lisboa Central - CHLC, Portugal). Eligible patients are male, younger than 65 years, with confirmed moderate to severe OSA, Apnoea-Hypopnea Index (AHI) above 15/h. Other sleep disorders, diabetes or any CV disease other than hypertension are exclusion criteria. Clinical evaluation at baseline includes Epworth Sleepiness Scale (ESS), and sleepiness is defined as ESS above 10. OSA will be confirmed by polygraphic study (cardiorespiratory, level 3). Participants are proposed to undertake assessment of carotid-femoral pulse wave velocity (cf-PWV) and 24 hours evaluation of Ambulatory Blood Pressure Monitoring (ABPM), at baseline and after 4 months of CPAP therapy. Compliance and effectiveness of CPAP will be assessed. The main outcome is variation of cf-PWV over time.

**Ethics and dissemination.** This protocol was approved by the Ethics Committees of CHLC (ref. 84/2012) and NOVA Medical School (nr.36/2014/CEFCM), Lisbon. Informed, written consent will be obtained. Its results will be presented at conferences and published in peer-reviewed journals.

**Registration.** ClinicalTrials.gov ID: NCT02273089.

### Strengths and limitations of this study protocol

- This study protocol allows us to obtain new evidence on the effectiveness of CPAP in decreasing cardiovascular risk in sleepy and non-sleepy male patients with OSA.
- The strengths of this protocol are the controlled, clinic-based setting, the use of standardized instruments to characterize OSA and sleepiness, and the use of standardized quantitative early indicators of cardiovascular risk (cf-PWV).
- This observational study protocol has the limitations of the convenience, non-randomized sample and the exclusion of patients with mild OSA or older patients.

### BACKGROUND

Obstructive sleep apnoea (OSA), if left untreated, is associated with high cardiovascular (CV) morbidity and mortality<sup>1,2,3</sup>.

The diagnosis of OSA syndrome is based on the presence of symptoms suggestive of the disorder, with confirmation by polygraphic sleep study<sup>4,5</sup>. The Epworth Sleepiness Scale (ESS) is a validated questionnaire that evaluates the presence of excessive daytime somnolence<sup>6</sup>. Other symptoms besides sleepiness are nonspecific (decreased concentration, irritability)<sup>4,5</sup>, hampering diagnosis.

Continuous positive airway pressure (CPAP) is the standard therapy for patients with symptomatic OSA, but CPAP therapy for asymptomatic patients is consensual only when the apnoea-hypopnea index (AHI) is above 30/hour<sup>7</sup>.

In some studies, a greater severity in polysomnographic parameters has been reported in sleepy patients in comparison with those who are not sleepy<sup>8,9</sup>.

Considering the relationship between OSA and CV disease, namely arterial hypertension or CV risk, it is also less evident in patients with fewer symptoms. The effect of CPAP in lowering blood pressure (BP) levels seems greater in patients with more severe OSA and sleepiness than in those without it<sup>10</sup>.

Changes in arterial stiffness are measurable and are one of the earliest manifestations of functional and structural damage to the vessel wall in the process of atherosclerosis. Arterial stiffness, evaluated by pulse wave velocity (PWV), is used as an early marker of



1  
2  
3 organ damage in hypertensive patients<sup>11</sup>. It predicts cardiovascular events, beyond  
4 classical CV risk factors, and can be considered as an intermediate endpoint for CV  
5 events<sup>12</sup>. Carotid-femoral pulse wave velocity (cf-PWV), i.e. the speed of the pulse as it  
6 travels from the heart to the carotid and the femoral artery, is the most commonly  
7 used non-invasive method to assess arterial stiffness and is considered the gold  
8 standard<sup>12,13</sup>.

9  
10 Increased arterial stiffness depends on various conditions, of which blood pressure and  
11 ageing prevail, but also on other CV risk factors.

12  
13 cf-PWV value is augmented in patients with OSA, even in those without high BP<sup>14,15</sup>. It  
14 is increased even in the less symptomatic, severe patients. There is an improvement  
15 after treatment with CPAP<sup>16</sup> but the effect in patients without sleepiness is less well  
16 known and still controversial<sup>17</sup>.

17  
18 This research protocol aims to assess the variation of arterial stiffness in two cohorts of  
19 patients with OSA, either sleepy or non-sleepy, while undergoing treatment with CPAP.  
20 We hypothesize that a measurable improvement on cf-PWV can be detected over  
21 time, independently of sleepiness.

## 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

### METHODS AND ANALYSIS

#### Study design

This project involves the prospective, observational study of a systematic, consecutive, non-randomized sample of adult male patients diagnosed with OSA and proposed to CPAP, recruited from a single outpatient sleep clinic (Centro Hospitalar de Lisboa Central - CHLC, Lisbon, Portugal).

The sample is divided into two cohorts according to the Epworth sleepiness scale (ESS) and the effect of CPAP therapy on sleepy (ESS>10) and non-sleepy (ESS≤10) patients will be compared (Figure 1).

The primary outcome is the variation of cf-PWV after therapy with CPAP. The effect of a four months trial of CPAP is assessed. For ethical reasons, each patient will be its own control.

Obesity and metabolic syndrome are common findings in OSA, and possible changes of metabolic parameters after CPAP are relevant<sup>18</sup>.

1  
2  
3 Secondary outcomes are ambulatory blood pressure measurements (ABPM) variations,  
4 as well as metabolic changes after treatment with CPAP.  
5

6 The study is exploratory in nature and is based on a convenience sample, limited by  
7 the number of eligible patients consenting to participate. Sample size was estimated  
8 for the primary outcome as an effective sample of 70 patients to demonstrate a  
9 reduction on cf-PWV from 12 m/s to 11 m/s (from baseline to 4 months on CPAP), with  
10 95% confidence and power 80%. Based on the previous assessment of the institutional  
11 experience on compliance with CPAP and with outpatient clinic consultations, the  
12 recruited sample was increased in 15% to 80 patients.  
13

14 Recruitment started on October 2012 and data collection is expected to end by June  
15 2016.  
16

#### 17 18 19 20 21 22 23 24 **Inclusion criteria**

25 Patients referred to the Outpatient Sleep Clinic of the Pneumology Department, CHLC,  
26 Lisbon, due to snoring or other complaints suggestive of OSA, are eligible for the study  
27 if they meet the following criteria: males, younger than 65 years old, living in Greater  
28 Lisbon and with confirmed moderate to severe OSA (AHI > 15/h). To confirm this, on  
29 the first consultation, data on anamnesis and clinical examination are collected and the  
30 Epworth questionnaire is applied.  
31  
32  
33  
34  
35  
36  
37

#### 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 **Exclusion criteria**

Patients are excluded if they have a history of cardiovascular events; established heart  
disease (beyond arterial hypertension); peripheral vascular disease. Smoking (over 10  
units pack/year) or alcohol intake (> 80 g / day) are not allowed. Other severe chronic  
diseases (assessed by chronic use of medication), chronic ingestion of hypnotics or  
other sleep disorders (clinically identified) are exclusion criteria.

Patients with diabetes are excluded, as they might have vascular involvement.

Some comorbidities are allowed, namely hypertension and metabolic syndrome.  
Antihypertensive medication and treatment of dyslipidemia are allowed as well.

#### **Baseline evaluation**

1  
2  
3 The Outpatient Sleep Clinic protocol for patients referred due to snoring or other  
4 complaints suggestive of OSA requires a clinical evaluation, blood tests,  
5 electrocardiogram and a sleep study.  
6  
7

8 ESS will be applied by the principal investigator, and the presence of comorbidities and  
9 pharmacotherapy in progress is evaluated.  
10

11 The collection of data regarding duration of comorbidity or pharmacotherapy has not  
12 been considered since including these two factors as accountable intervening factors  
13 would greatly increase the sample size.  
14  
15

16 Anthropometric data regarding adiposity and vital signs are collected. Body mass index  
17 (BMI) is calculated as weight (kg) divided by height (m) squared.  
18

19 BP will be measured while the patient is seated in a quiet room, using a semi-  
20 automatic device (Omron HEM-907XL, Omron Healthcare, Bannockburn, IL, USA) with  
21 an appropriate cuff. The patient could not have taken stimulant substances 3 hours  
22 prior to the BP assessment. Two measurements are taken with a minimum of 3-min  
23 intervals and the average considered. When large differences existed among them,  
24 additional measurements were performed.  
25  
26  
27  
28  
29  
30

31 The analytical screening evaluation includes HbA1c, fasting glucose, total cholesterol,  
32 HDL, LDL and triglycerides; in patients with high levels of fasting glucose, an oral  
33 glucose tolerance test will be performed. Dyslipidaemia, glucose intolerance and  
34 metabolic syndrome are diagnosed according to current guidelines<sup>19</sup>.  
35  
36  
37

38 An electrocardiogram (Page Writer TC 30, Philips, Eindhoven, NL) will be done by the  
39 same technicians, per institutional protocol.  
40  
41  
42

#### 43 **Sleep study**

44 To confirm the diagnosis of OSA, patients will submit to a polygraphic sleep study type  
45 3, cardiorespiratory (Embletta® system, Broomfield, USA), a technical outpatient  
46 registration, which includes the continuous recording from nasal cannula (pressure and  
47 flow), thoracic-abdominal motion, pulse oximetry, electrocardiogram and body  
48 position sensor. Results from the sleep studies are analyzed by two trained  
49 technicians, using standard criteria<sup>20</sup>.  
50  
51  
52  
53  
54  
55  
56  
57

#### 58 **Ambulatory Blood Pressure Monitoring**

1  
2  
3 All participants will undertake 24 hours blood pressure monitoring with Ambulatory  
4 Blood Pressure - SpaceLabs model 90207® (Issaquah, WZ, USA), according to the  
5 current guidelines. Patients are classified as normotensive if the average systolic and  
6 diastolic BP values obtained by ABPM are within normal limits; and are classified as  
7 hypertensive if either already on antihypertensive medication or if the average BP  
8 values obtained by ABPM are above  $\geq 130$  mmHg of systolic and/or  $\geq 80$  mmHg diastolic  
9 BP<sup>11</sup>.

### 16 17 **Pulse wave velocity**

18 Non-invasive assessment of cf-PWV (Complior®, Colson, Paris, France) will be  
19 performed by the same operator. For this, the investigators followed the recently  
20 published expert consensus document<sup>21</sup>. In a few words, measurement is done at the  
21 right common carotid and right common femoral arteries after 10 min rest in supine  
22 position. Two pressure waveforms were transcutaneously recorded at the base of the  
23 neck for the right common carotid artery and over the right femoral artery. Pulse  
24 transit time was determined as the average of 10 consecutive beats. The straight-line  
25 distance between the measurement sites is obtained by surface measurement, with  
26 the patient in the supine position. cf-PWV is calculated as the ratio of distance to  
27 transit time. In order to normalize cf-PWV values according to the arterial pathway, the  
28 threshold of 10 m/s for cf-PWV evaluated by the full direct carotid-to-femoral distance  
29 was considered<sup>21</sup>.

### 39 40 41 **Standard CPAP Intervention**

42 According to the current clinical recommendations<sup>4</sup>, patients with moderate or severe  
43 OSA are offered therapy with non-invasive ventilation by CPAP. Additionally, patients  
44 receive counselling on sleep hygiene.

45 An automatic auto-CPAP device (ResMed S9 AutoSet, California, USA) is used. CPAP  
46 will be titrated for 3 nights. The definitive value of CPAP is the amount of pressure that  
47 eliminates events in approximately 95% of the total sleep time (95<sup>th</sup> percentile), once  
48 confirmed there is no significant leakage and use of nasal mask<sup>22</sup>.

49 Patients will be assessed monthly for compliance and effectiveness of the intervention.  
50 The compliance to the CPAP is measured using data from the CPAP's card; a patient is  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 considered in compliance when using CPAP at least 4h/day (average) of at least 70% of  
4 nights. CPAP is considered effective if the AHI falls below 5/h<sup>23</sup>.

5  
6 The presence of nasal complaints or changes on the equipment will be taken into  
7  
8 account.  
9

### 10 11 **Follow-up assessments**

12 After 4 months of standard CPAP intervention, patients will undergo a clinical  
13 evaluation, including ESS, and analytical evaluation, similar to the one on baseline.  
14 BMI, ABPM and cf-PWV will be assessed, as well as compliance to CPAP and the  
15 effectiveness of CPAP therapy.  
16

17 At any point of the study, patients will be excluded from follow-up if do not comply  
18 with CPAP, if significant weight loss (greater than 10%) occurs<sup>4</sup>, if new drugs are  
19 prescribed or if new diseases are diagnosed.  
20  
21

### 22 23 **Statistical analyses**

24 The primary outcome measure (cf-PWV) is compared before and after therapy with  
25 CPAP for four months. Analysis is performed as per intention-to-treat.  
26

27 Continuous variables are described with median and interquartile range (IQR, 25th  
28 percentile to 75th percentile) or extreme values, as previous evaluations have  
29 evidenced that a normal distribution of values was not to be expected. Data of sleepy  
30 and non-sleepy subjects at each evaluation are compared using the Mann-Whitney  
31 test. Categorical variables are described as percentage and are compared with  
32 Pearson's chi-square test or Fisher's exact test; stratified Mantel-Haenszel analysis is  
33 performed as appropriate.  
34

35 The categorized outcome measure (using the threshold of 10 m/s for cf-PWV<sup>21</sup>) is used  
36 to estimate incidence rates of the outcomes and relative risk estimates, both with 95%  
37 confidence intervals.  
38

39 Measurements on the cohort subjects before and after 4 months of CPAP are analyzed  
40 using generalized linear mixed-effects models for repeated longitudinal data, to  
41 explore associations between outcomes and exposures, in order to assess factors  
42 influencing the success of the intervention.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## DISCUSSION

The results of this study will disclose differences in the CV risk and the response to CPAP therapy among patients with and without daytime sleepiness. In the subgroup of less symptomatic patients, the benefits of CPAP have yet to be identified.

This observational study protocol has the limitations of the convenience, non-randomized sample, and the exclusion of patients with mild OSA or older patients. The strengths of this protocol are the controlled, clinic-based setting, the use of standardized instruments to characterize OSA and sleepiness, and the use of standardized quantitative early indicators of cardiovascular risk (cf-PWV), a useful indicator of subclinical CV disease.

### Ethics and dissemination

This protocol was both approved by the Ethics Committees of CHLC (ref. 84/2012) and NOVA Medical School (nr.36/2014/CEFCM), Lisbon. It has been registered as STIFFSLEEP at ClinicalTrials.gov (ID: NCT02273089). Informed, written consent will be obtained. Results will be presented at conferences and published in peer-reviewed journals.

**Funding statement** This work was supported by the Pneumology Department, CHLC, Lisbon, and by a gracious grant from Vitalaire SA (Lisbon).

**Author's contributors** Alexandra Mineiro developed the conceptual clinical background of the protocol; Pedro Marques da Silva provided clinical background and methodological input for the cardiovascular risk assessment; Marta Alves and Daniel Virella contributed to the epidemiologic design, causal framework and proposed epidemiologic and statistical analyses; Maria João Marques-Gomes and João Cardoso provided scientific overview. All authors provided intellectual input into the editing of the manuscript and preparation of publication.

**Funding** The work was supported by Pneumology Department, CHLC, Lisbon, and Vitalaire SA.

**Competing interests** None

1  
2  
3 **Patient consent** Obtained

4 **Provenance and peer review** Not commissioned; externally peer reviewed

5  
6  
7  
8  
9 **REFERENCES**

- 10  
11 1. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality:  
12 eighteen-year follow-up of the Wisconsin Sleep Cohort. *Sleep* 2008;31:1071-78.
- 13 2. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in  
14 men with obstructive sleep apnoea-hypopnoea with or without treatment with  
15 continuous positive airway pressure: an observational study. *Lancet*  
16 2005;365:1046-53.
- 17 3. Peker Y, Hedner J, Norum J, et al. Increased Incidence of Cardiovascular Disease  
18 in Middle-aged Men with Obstructive Sleep Apnea. A 7-Year Follow-up. *Am J*  
19 *Respir Crit Care Med* 2002;166:159-65.
- 20 4. Epstein LJ, Kristo D, Strollo PJ, et al. Clinical guideline for the evaluation,  
21 management and long-term care of obstructive sleep apnea in adults. Adult  
22 Obstructive Sleep Apnea Task Force of the American Academy of Sleep  
23 medicine. *Journal of Clinical Sleep Medicine* 2009;5(nº3):263-76.
- 24 5. McNicholas WT. Diagnosis of Obstructive Sleep Apnea in Adults. *Proc Am*  
25 *Thorac Soc* 2008;5:154-60.
- 26 6. Johns MW. A new method for measuring daytime sleepiness: the Epworth  
27 sleepiness scale. *Sleep* 1991;14:540-5.
- 28 7. Lloberes P, Durán-Cantolla J, Martínez-García MA, et al. SEPAR Guidelines.  
29 Diagnosis and treatment of sleep apnea-hypopnea syndrome. *Arch*  
30 *Bronconeumol*. 2011;47(3):143-156
- 31 8. Oksenberg A. et al. Severe obstructive sleep apnea: sleepy versus non sleepy  
32 patients. *Laryngoscope* 2010 Mar; 120 (3): 643-8.
- 33 9. Kapur VK, Baldwin CM, Resnick HE, et al. Sleepiness in patients with moderate  
34 to severe sleep-disordered breathing. *Sleep* 2005; 28(4); 472-77
- 35 10. Bratton DJ, Stradling JR, Barbé F, et al. Effect of CPAP on blood pressure in  
36 patients with minimally symptomatic obstructive sleep apnoea: a meta-analysis
- 37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 using individual patient data from four randomised controlled trials. *Thorax*  
4 2014;0:1–8.  
5

- 6  
7 11. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Guidelines for the Management  
8 of Arterial Hypertension: The Task Force for the Management of Arterial  
9 Hypertension of the European Society of Hypertension (ESH) and of the  
10 European Society of Cardiology (ESC). *J Hypertens* 2013; 31:1281–1357.  
11  
12 12. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers  
13 for primary and secondary prevention. A position paper from the European  
14 Society of Cardiology Working Group on peripheral circulation: Endorsed by the  
15 Association for Research into Arterial Structure and Physiology (ARTERY)  
16 Society. *Atherosclerosis* 2015;241(2):507-532.  
17  
18 13. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events  
19 and all-cause mortality with arterial stiffness. A systematic review and meta-  
20 analysis. *JACC* 2010; 55 (nº13):1318-27.  
21  
22 14. Doonan RJ, Scheffler P, Lalli M, et al. Increased arterial stiffness in obstructive  
23 sleep apnoea: a systematic review. *Hypertension Research* 2011;34:23-32.  
24  
25 15. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in  
26 obstructive sleep apnea. *Am J Respir Crit Care Med* 2005;172:613-18.  
27  
28 16. Vlachantonil T, Dikaiakou E, Antonopoulos C, et al. Effects of continuous  
29 positive airway pressure (CPAP) treatment for obstructive sleep apnea in  
30 arterial stiffness: A meta-analysis. *Sleep Med Rev* 2013;17(1):19-28.  
31  
32 17. Wons AM, Kohler M. Established vascular effects of continuous positive airway  
33 pressure therapy in patients with obstructive sleep apnoea – an update. *J*  
34 *Thorac Dis* 2015;7(5):912-919.  
35  
36 18. Mota PC, Drummond M, Winck JC, et al. APAP impact on metabolic syndrome  
37 in obstructive sleep apnea patients. *Sleep Breath* 2011;15(4):665-72.  
38  
39 19. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a  
40 joint interim statement of the International Diabetes Federation Task Force on  
41 Epidemiology and Prevention; National Heart, Lung, and Blood Institute;  
42 American Heart Association; World Heart Federation; International  
43 Atherosclerosis Society; and International Association for the Study of Obesity.  
44 *Circulation* 2009 Oct20;120(16):1640-5  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 20. Iber CI, Ancoli-Israel S, Chesson L, et al. for the American Academy of Sleep  
4 Medicine. Rules, terminology and technical specifications: *The AASM Manual*  
5 *for Scoring of Sleep and Associated Events*; 2007.  
6  
7  
8 21. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on  
9 the measurement of aortic stiffness in daily practice using carotid-femoral  
10 pulse wave velocity. *J Hypertens* 2012;30:445-448.  
11  
12 22. Masa JF, Jiménez A., Duran J., et al. Alternative Methods of Titrating  
13 Continuous Positive Airway Pressure. A Large Multicenter Study. *Am J Respir*  
14 *Crit Care Med* 2004;170:1218-1224  
15  
16 23. Schwab RJ, Badr SM, Epstein LJ, et al. An Official American Thoracic Society  
17 Statement: Continuous Positive Airway Pressure Adherence Tracking Systems.  
18 The optimal monitoring strategies and outcome measures in adults. *Am J Respir*  
19 *Crit Care Med* 2013;188(5):613-620.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Fig.1 Study design  
173x233mm (300 x 300 DPI)